Evidence map›Paper›PMID 26747051›Full record

Trial reportContemporary clinical trials2016

Determining the effects and challenges of incorporating genetic testing into primary care management of hypertensive patients with African ancestry.

C R Horowitz, N S Abul-Husn, S Ellis, M A Ramos, R Negron, M Suprun, R E Zinberg, T Sabin, D Hauser, N Calman and 2 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Contemporary clinical trials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Review
  17. Successful recruitment and retention of diverse participants in a genomics clinical trial: a good invitation to a great party.Genetics in medicine : official journal of the American College of Medical Genetics · 2019
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

C R HorowitzDepartment of Population Health Sciences and Policy, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1077, New York, NY 10029, USA; Center for Health Equity and Community Engaged Research, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1077, New York, NY, 10029, USA; The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, 1468 Madison Avenue, Annenberg Building, 18th Floor, Room 18-16, New York, NY 10029, USA. Electronic address: carol.horowitz@mssm.edu.
N S Abul-HusnThe Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, 1468 Madison Avenue, Annenberg Building, 18th Floor, Room 18-16, New York, NY 10029, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1022, New York, NY 10029, USA. Electronic address: noura.abul-husn@mssm.edu.
S EllisThe Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, 1468 Madison Avenue, Annenberg Building, 18th Floor, Room 18-16, New York, NY 10029, USA. Electronic address: steve.ellis@mountsinai.org.
M A RamosDepartment of Population Health Sciences and Policy, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1077, New York, NY 10029, USA; Center for Health Equity and Community Engaged Research, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1077, New York, NY, 10029, USA. Electronic address: michelle.ramos@mountsinai.org.
R NegronYale Institute for Network Science, Yale University, 17 Hillhouse Avenue, P.O. Box 208263, New Haven, CT 06520, USA. Electronic address: rennie.negron@yale.edu.
M SuprunDepartment of Population Health Sciences and Policy, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1077, New York, NY 10029, USA. Electronic address: maria.suprun@mountsinai.org.
R E ZinbergDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1022, New York, NY 10029, USA. Electronic address: randi.zinberg@mssm.edu.
T SabinDepartment of Population Health Sciences and Policy, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1077, New York, NY 10029, USA. Electronic address: tatiana.sabin@mountsinai.org.
D HauserInstitute for Family Health, 16 East 16th Street, New York, NY 10003, USA. Electronic address: dhauser@institute.org.
N CalmanCenter for Health Equity and Community Engaged Research, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1077, New York, NY, 10029, USA; Institute for Family Health, 16 East 16th Street, New York, NY 10003, USA. Electronic address: ncalman@institute.org.
E BagiellaDepartment of Population Health Sciences and Policy, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1077, New York, NY 10029, USA. Electronic address: emilia.bagiella@mssm.edu.
E P BottingerThe Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, 1468 Madison Avenue, Annenberg Building, 18th Floor, Room 18-16, New York, NY 10029, USA; Berlin Institute of Health, Berlin, Germany. Electronic address: erwin.bottinger@mssm.edu.
Icahn School of Medicine at Mount Sinai · USInstitute for Family Health · USYale University · US

Funding

MSHS Translational Science HubUL1TR001433 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WRIGHT, ROSALIND J · 2015 to 2019
$26.6M
Mount Sinai Institutes for Clinical and Translational SciencesUL1TR000067 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SAMPSON, HUGH A · 2012 to 2014
$16.5M
Disseminating Effective Community-Led Programs to Elimanate Diabetes DisparitiesR24MD001691 · NIMHD · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI HOROWITZ, CAROL R · 2005 to 2015
$6.0M
Genomic Medicine Pilot For Hypertension And Kidney Disease In Primary CareU01HG007278 · NHGRI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOROWITZ, CAROL R · 2013 to 2018
$5.7M
T32 training grant in medical genetics.T32GM082773 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Laszlo Tamas Kozicz, Eva Morava-Kozicz · 2008 to 2026
$4.9M
Biorepository for Genomic Medicine in diverse CommunitiesU01HG006380 · NHGRI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BOTTINGER, ERWIN P. · 2011 to 2015
$4.5M
NCATS NIH HHS UL1 TR000067NCATS NIH HHS UL1TR000067NCATS NIH HHS UL1 TR001433NHGRI NIH HHS 5U01HG007278NHGRI NIH HHS U01 HG006380NHGRI NIH HHS U01HG006380NHGRI NIH HHS U01 HG007278NIGMS NIH HHS T32 GM082773NIMHD NIH HHS R24 MD001691
6 · The paper itself

Abstract

People of African ancestry (Blacks) have increased risk of kidney failure due to numerous socioeconomic, environmental, and clinical factors. Two variants in the APOL1 gene are now thought to account for much of the racial disparity associated with hypertensive kidney failure in Blacks. However, this knowledge has not been translated into clinical care to help improve patient outcomes and address disparities. GUARDD is a randomized trial to evaluate the effects and challenges of incorporating genetic risk information into primary care. Hypertensive, non-diabetic, adults with self-reported African ancestry, without kidney dysfunction, are recruited from diverse clinical settings and randomized to undergo APOL1 genetic testing at baseline (intervention) or at one year (waitlist control). Providers are educated about genomics and APOL1. Guided by a genetic counselor, trained staff return APOL1 results to patients and provide low-literacy educational materials. Real-time clinical decision support tools alert clinicians of their patients' APOL1 results and associated risk status at the point of care. Our academic-community-clinical partnership designed a study to generate information about the impact of genetic risk information on patient care (blood pressure and renal surveillance) and on patient and provider knowledge, attitudes, beliefs, and behaviors. GUARDD will help establish the effective implementation of APOL1 risk-informed management of hypertensive patients at high risk of CKD, and will provide a robust framework for future endeavors to implement genomic medicine in diverse clinical practices. It will also add to the important dialog about factors that contribute to and may help eliminate racial disparities in kidney disease.

Indexed as

AdolescentAdultAgedApolipoprotein L1ApolipoproteinsBlack or African AmericanDecision Support TechniquesGenetic CounselingGenetic Predisposition to DiseaseGenetic TestingHumansHypertensionLipoproteins, HDLMiddle AgedPolymorphism, GeneticPrimary Health CareAPOL1 protein, humanApolipoprotein L1ApolipoproteinsLipoproteins, HDLAfrican ancestryChronic kidney diseaseCommunity-based researchDisparitiesGeneticsRace

Identifiers

PMID26747051
PMCPMC4818169
OpenAlexW2220023844

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.